Skip to main content

Table 1 Baseline characteristics of all subjects

From: Characteristics of the pulmonary opacities on chest CT associated with difficulty in short-term liberation from veno-venous ECMO in patients with severe ARDS

 

sECMO group (n = 72)

dsECMO group (n = 81)

P

Age, y

60.5 (49.0–69.0)

65.0 (53.5–71.5)

0.06

Sex, male, n (%)

56 (77.8)

64 (79.0)

> 0.99

BMI, kg/m2, a

23.6 (21.8–29.0)

24.8 (22.4–28.3)

0.38

Past medical history

   

 Hypertension, n (%)

23 (31.9)

32 (39.5)

0.40

 Diabetes, n (%)

21 (29.2)

18 (22.2)

0.36

 Chronic kidney disease, n (%)

8 (11.1)

6 (7.4)

0.58

 COPD, n (%)

6 (8.3)

7 (8.6)

> 0.99

 Asthma, n (%)

3 (4.2)

4 (4.9)

> 0.99

 Interstitial lung diseases, n (%)

5 (6.9)

6 (7.4)

> 0.99

 Lung cancer, n (%)

3 (4.2)

7 (8.6)

0.34

 Chronic heart failure, n (%)

3 (4.2)

6 (7.4)

0.50

Interval MV-ECMO > 7 days, n (%)

4 (5.6)

13 (16.1)

0.04

Primary reason for ARDS, n (%)

  

0.11

 Pneumonia

58 (80.6)

68 (84.0)

 

  Bacterial

28 (38.9)

19 (23.5)

 

  Influenza

9 (12.5)

6 (7.4)

 

  COVID-19

11 (15.3)

20 (24.7)

 

  Others

10 (13.9)

23 (28.4)

 

 Extra-pulmonary

5 (6.9)

6 (7.4)

 

 Drowning

5 (6.9)

5 (6.2)

 

 Trauma

4 (5.6)

2 (2.5)

 

Use of muscle relaxants before ECMO support, n (%)

27 (37.5)

36 (44.4)

0.41

Prone positioning before ECMO support, n (%)

5 (6.9)

10 (12.4)

0.29

SOFA score at ECMO instauration

12.5 (11.0–14.0)

13.0 (12.0–15.0)

0.10

PF ratio just before ECMO instauration

70.9 (57.8–90.0)

74.0 (55.4–95.6)

0.59

PEEP at the timing of CT examination, cmH2O

10 (8–12)

10 (10–14)

0.13

Use of steroid within the first 2 weeks of ECMO support, n (%)

35 (48.6)

48 (60.0)

0.19

Use of muscle relaxants within the first 48 h of ECMO support, n (%)

32 (44.4)

44 (54.3)

0.26

Prone positioning within the first 2 weeks of ECMO support, n (%)

3 (4.2)

4 (4.9)

> 0.99

Duration of ECMO run, days

7.0 (5.3-9.0)

19.0 (15.0-28.5)

< 0.001

Re-canulation of ECMO, n (%)

0 (0.0)

11 (13.6)

< 0.001

Mortality at 14 days after ECMO support, n (%)

0 (0.0)

8 (9.9)

0.007

Mortality at hospital discharge, n (%)

9 (12.5)

49 (60.5)

< 0.001

  1. Data are presented as the median and interquartile ranges (25–75% percentile), or as absolute frequencies with percentages
  2. Abbreviations: sECMO group, successful short-term liberation from ECMO group; dsECMO group, difficulty in short-term liberation from ECMO group; BMI, body mass index; COPD, chronic obstructive pulmonary disease; MV, mechanical ventilation; ECMO, extracorporeal membrane oxygenation; ARDS, acute respiratory distress syndrome; COVID-19, coronavirus disease 2019; SOFA score, sequential organ failure assessment score; PF ratio, PaO2/FIO2 ratio; PEEP, positive end-expiratory pressure
  3. aMissing value = 3
Back to article page

Respiratory Research

ISSN: 1465-993X

Contact us